Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$36.42 USD
+0.58 (1.62%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $36.45 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COLL 36.42 +0.58(1.62%)
Will COLL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COLL
Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Zacks.com featured highlights AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Other News for COLL
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
Commit To Purchase Collegium Pharmaceutical At $17.50, Earn 6.7% Annualized Using Options
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
Collegium Pharmaceutical to redeem outstanding 2.625% convertible senior notes due 2026